Two UK Companies Shortlisted for EuropaBio Most Innovative EU Biotech SME Award
News Sep 23, 2013
UK companies dominate the shortlist for this year's EuropaBio Most Innovative EU Biotech SME Award. Entering its fourth year, the award has grown rapidly, with applications coming from all three sectors of biotechnology - healthcare, industrial and agricultural, all providing solutions to major societal unmet needs.
This year, two out of the five shortlisted firms come from the UK:
• e-Therapeutics, a UK biotech SME based in Oxford and Newcastle has pioneered 'network pharmacology,' a new approach to drug discovery based on advances in network science and chemical biology, with which it seeks novel treatments for complex diseases, principally cancer and disorders of the nervous system.
• PsiOxus Therapeutics, based in Oxfordshire, is developing a new approach to cancer therapy by using the processes of directed evolution to develop a virus that is a potent killer of cancer cells but with minimal effects on normal healthy cells.
Steve Bates, BIA Chief Executive Officer, said: "Having two out of the five shortlisted companies shows the strength of the UK biotech sector in Europe. It is great to see BIA member companies getting the recognition they deserve in this prestigious European competition."
The award will be presented during the first ever European Biotechnology Week, at an event in Brussels on 2 October.
The shortlisted companies have received two year's free membership of EuropaBio, and the over-all winner will receive €10,000.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE